OCR002-SP103 - Oral Immediate Release Study
Phase 1
Completed
- Conditions
- Cirrhosis
- Interventions
- Drug: OCR-002 IV SolutionDrug: OCR-002 IR Oral TabletDrug: OCR-002 Oral Solution
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Ocera Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03846843
- Locations
- 🇺🇸
Southern California Research Center, Coronado, California, United States
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
Phase 2
Completed
- Conditions
- Hepatic EncephalopathyAcute Episode of Overt Hepatic Encephalopathy
- Interventions
- Drug: placebo intravenous infusion
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Ocera Therapeutics, Inc.
- Target Recruit Count
- 231
- Registration Number
- NCT01966419
Emergency Use of OCR-002 in Acute Liver Failure (ALF)
- Conditions
- Acute Liver Failure
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Ocera Therapeutics, Inc.
- Registration Number
- NCT01634230
- Locations
- 🇺🇸
University of Arkansas, Little Rock, Arkansas, United States
© Copyright 2025. All Rights Reserved by MedPath